Clinical Trials Browser

Phase 2/3 × Sorafenib × Other hematologic neoplasm × Clear all

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05313958 2023-07-27

SCCLG-M5

Phase 2/3 Recruiting

Other hematologic neoplasm

Leukemia, Monocytic, Acute

NCT02474290 2019-08-26

Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Phase 2/3 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute